A phase I/II study of C019199 in combination with sintilimab in advanced malignancy. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...
The results of research by scientists at Barts Cancer Institute at Queen Mary University of London has identified a sequential drug treatment approach that can reverse the resistance of leukemia cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results